DILI: Clinical Trials and Post-Marketing

This course is led by a Hepatologist with extensive experience in clinical assessment of DILI and who published ‘RUCAM’ the widely used causality assessment method of DILI.

返回 Agenda

SESSION 6: HOW TO MONITOR AND PREVENT DILI IN POST AUTHORISATION PHASE

Session Chair(s)

Gaby L. Danan, MD, PHD

Pharmacovigilance Expert

GLD, France

Principles and examples

Speaker(s)

HOW TO MONITOR AND PREVENT DILI IN POST AUTHORISATION PHASE

Gaby L. Danan, MD, PHD

GLD, France

Pharmacovigilance Expert

DILI: Clinical Trials and Post-Marketing

SESSION 6: HOW TO MONITOR AND PREVENT DILI IN POST AUTHORISATION PHASE

Session Chair(s)

Gaby L. Danan, MD, PHD

Speaker(s)

HOW TO MONITOR AND PREVENT DILI IN POST AUTHORISATION PHASE

获得信息并保持参与